CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans." …
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Myrio Therapeutics partners with leading US research institutions to advance T cell immunotherapies for solid tumours
October 28, 2025 - - Australian Biotech -
MTPConnect signs cooperation agreement with Saudi Ministry of Health to boost life sciences collaboration
October 28, 2025 - - Australian Biotech -
Australians want better access to medical technology, and a clearer pathway to get there
October 28, 2025 - -
Pharmacy Guild backs expanded prescribing rights for optometrists
October 28, 2025 - - Latest News -
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech